JP2016540759A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016540759A5 JP2016540759A5 JP2016535047A JP2016535047A JP2016540759A5 JP 2016540759 A5 JP2016540759 A5 JP 2016540759A5 JP 2016535047 A JP2016535047 A JP 2016535047A JP 2016535047 A JP2016535047 A JP 2016535047A JP 2016540759 A5 JP2016540759 A5 JP 2016540759A5
- Authority
- JP
- Japan
- Prior art keywords
- agents
- subject
- assay
- cell cycle
- timp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 26
- 238000003556 assay Methods 0.000 claims 22
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 claims 10
- 108010008598 insulin-like growth factor binding protein-related protein 1 Proteins 0.000 claims 10
- 210000001124 body fluid Anatomy 0.000 claims 6
- 230000006370 G0 arrest Effects 0.000 claims 5
- 230000037057 G1 phase arrest Effects 0.000 claims 5
- 239000010839 body fluid Substances 0.000 claims 5
- 208000033626 Renal failure acute Diseases 0.000 claims 4
- 201000011040 acute kidney failure Diseases 0.000 claims 4
- 239000000090 biomarker Substances 0.000 claims 4
- 230000006369 cell cycle progression Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 3
- 210000002919 epithelial cell Anatomy 0.000 claims 3
- 210000001985 kidney epithelial cell Anatomy 0.000 claims 3
- 229930105110 Cyclosporin A Natural products 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 239000000411 inducer Substances 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 2
- 102100032814 ATP-dependent zinc metalloprotease YME1L1 Human genes 0.000 claims 1
- QEEBRPGZBVVINN-UHFFFAOYSA-N Desacetyl-bufotalin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C1(O)CCC2C=1C=CC(=O)OC=1 QEEBRPGZBVVINN-UHFFFAOYSA-N 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 claims 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims 1
- -1 NC381 Chemical compound 0.000 claims 1
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 claims 1
- 229950010817 alvocidib Drugs 0.000 claims 1
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 claims 1
- 229960004991 artesunate Drugs 0.000 claims 1
- QEEBRPGZBVVINN-BMPKRDENSA-N bufalin Chemical compound C=1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5(CC[C@H](O)C[C@H]5CC4)C)CC[C@@]32C)C=CC(=O)OC=1 QEEBRPGZBVVINN-BMPKRDENSA-N 0.000 claims 1
- 238000007675 cardiac surgery Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 230000025084 cell cycle arrest Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 231100000417 nephrotoxicity Toxicity 0.000 claims 1
- 229960002404 palifermin Drugs 0.000 claims 1
- PIRWNASAJNPKHT-SHZATDIYSA-N pamp Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 PIRWNASAJNPKHT-SHZATDIYSA-N 0.000 claims 1
- 238000012959 renal replacement therapy Methods 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 1
- 229960004066 trametinib Drugs 0.000 claims 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 238000007631 vascular surgery Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361911406P | 2013-12-03 | 2013-12-03 | |
| US61/911,406 | 2013-12-03 | ||
| PCT/US2014/068337 WO2015084939A1 (en) | 2013-12-03 | 2014-12-03 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019202233A Division JP7068256B2 (ja) | 2013-12-03 | 2019-11-07 | 腎損傷および腎不全の診断および予後のための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016540759A JP2016540759A (ja) | 2016-12-28 |
| JP2016540759A5 true JP2016540759A5 (https=) | 2018-01-18 |
Family
ID=53274065
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016535047A Pending JP2016540759A (ja) | 2013-12-03 | 2014-12-03 | 腎損傷および腎不全の診断および予後のための方法および組成物 |
| JP2019202233A Active JP7068256B2 (ja) | 2013-12-03 | 2019-11-07 | 腎損傷および腎不全の診断および予後のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019202233A Active JP7068256B2 (ja) | 2013-12-03 | 2019-11-07 | 腎損傷および腎不全の診断および予後のための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US10300108B2 (https=) |
| EP (1) | EP3077819A4 (https=) |
| JP (2) | JP2016540759A (https=) |
| CN (2) | CN105917229B (https=) |
| WO (1) | WO2015084939A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ607703A (en) | 2008-10-21 | 2014-09-26 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| JP5763098B2 (ja) | 2009-12-20 | 2015-08-12 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| NZ605698A (en) | 2010-06-23 | 2015-03-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| ES2734494T3 (es) | 2011-12-08 | 2019-12-10 | Astute Medical Inc | Métodos y usos para el diagnóstico de una lesión renal y de una insuficiencia renal |
| TR201807542T4 (tr) | 2013-01-17 | 2018-06-21 | Astute Medical Inc | Böbrek hasarı ve böbrek yetmezliği teşhisi ve prognozuna yönelik metotlar ve bileşimler. |
| US10300108B2 (en) | 2013-12-03 | 2019-05-28 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US11243202B2 (en) | 2015-04-09 | 2022-02-08 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP3465201A4 (en) | 2016-06-06 | 2020-08-26 | Astute Medical, Inc. | MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR |
| ES2859487T3 (es) * | 2016-10-05 | 2021-10-04 | Mitobridge Inc | Métodos para tratar las lesiones renales agudas |
| WO2018081447A1 (en) * | 2016-10-26 | 2018-05-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Compositions and methods for reducing the rick of radiocontrast-induced nephropathy |
| CN110352073A (zh) * | 2016-10-28 | 2019-10-18 | 机敏医药股份有限公司 | 针对timp-2的抗体用于改善肾功能的用途 |
| US11346846B2 (en) | 2017-02-06 | 2022-05-31 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US11718682B2 (en) | 2017-04-05 | 2023-08-08 | Astute Medical, Inc. | Assays for TIMP2 having improved performance in biological samples |
| IL271564B2 (en) | 2017-06-23 | 2024-06-01 | Aki Therapeutics Aps | Compositions for the prevention and treatment of acute renal injury |
| IT201900001365A1 (it) * | 2019-01-30 | 2020-07-30 | Torino Politecnico | Sistema di monitoraggio e previsione della diuresi per il calcolo del rischio di insufficienza renale, e relativo metodo |
| AU2020363688A1 (en) | 2019-10-12 | 2022-04-21 | Farsight Medical Technology (Shanghai) Co., Ltd. | Treatment and prevention of nephrotoxin-induced kidney injuries |
| CN112316150B (zh) * | 2020-12-04 | 2023-04-28 | 深圳市中医院 | 一种用于预防或治疗代谢或损伤相关疾病的药物组合物 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
| US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
| CA2072758A1 (en) | 1990-09-14 | 1992-03-15 | Kenneth Francis Buechler | Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays |
| US5955377A (en) | 1991-02-11 | 1999-09-21 | Biostar, Inc. | Methods and kits for the amplification of thin film based assays |
| CA2107894C (en) | 1991-04-10 | 2003-10-14 | Kenneth F. Buechler | Crosstalk inhibitors and their uses |
| EP0579767B1 (en) | 1991-04-11 | 2000-08-23 | Biosite Diagnostics Inc. | Novel conjugates and assays for simultaneous detection of multiple ligands |
| US5324634A (en) | 1992-03-31 | 1994-06-28 | The Research Foundation Of State University Of New York | Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer |
| US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
| US6019944A (en) | 1992-05-21 | 2000-02-01 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membranes |
| US5494829A (en) | 1992-07-31 | 1996-02-27 | Biostar, Inc. | Devices and methods for detection of an analyte based upon light interference |
| US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
| US6140045A (en) | 1995-03-10 | 2000-10-31 | Meso Scale Technologies | Multi-array, multi-specific electrochemiluminescence testing |
| US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
| US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| AU2055400A (en) | 1998-12-18 | 2000-07-03 | Human Genome Sciences, Inc. | Prostacyclin-stimulating factor-2 |
| CA2356174A1 (en) | 1998-12-21 | 2000-06-29 | Monash University | Kidney disease detection and treatment |
| US20040126767A1 (en) | 2002-12-27 | 2004-07-01 | Biosite Incorporated | Method and system for disease detection using marker combinations |
| US20040253637A1 (en) | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
| JP2003081838A (ja) | 2001-09-11 | 2003-03-19 | Rohto Pharmaceut Co Ltd | グルコサミン製剤 |
| GB0130557D0 (en) | 2001-12-20 | 2002-02-06 | Serono Internat S A | Proteins |
| US7138230B2 (en) | 2002-12-06 | 2006-11-21 | Renovar, Inc. | Systems and methods for characterizing kidney diseases |
| US7560244B2 (en) | 2003-06-04 | 2009-07-14 | Joslin Diabetes Center, Inc. | Method of evaluating a subject for risk or predisposition of reduced renal function over time |
| US20050084880A1 (en) | 2003-07-11 | 2005-04-21 | Ronald Duman | Systems and methods for diagnosing & treating psychological and behavioral conditions |
| AU2004260083B2 (en) | 2003-07-17 | 2011-04-07 | Pacific Edge Limited | Markers for detection of gastric cancer |
| WO2006008661A2 (en) | 2004-07-19 | 2006-01-26 | Neurochem (International) Limited | Diagnostic methods of multiple organ amyloidosis |
| WO2006010529A1 (en) | 2004-07-28 | 2006-02-02 | F. Hoffmann-La Roche Ag | Timp-2 as target/marker of beta cell failure |
| US20080090759A1 (en) | 2004-08-30 | 2008-04-17 | Robert Kokenyesi | Methods and kits for predicting risk for preterm labor |
| ITVI20050059A1 (it) | 2005-03-04 | 2006-09-05 | Consorzio Per Gli Studi Universitari In Verona | Nuovi biomarcatori per la diagnosi e/o la prognosi di neoplasie in animali |
| CA2603550A1 (en) | 2005-03-31 | 2006-10-05 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for diagnosing and treating neuropsychiatric disorders |
| US20070087387A1 (en) | 2005-04-21 | 2007-04-19 | Prasad Devarajan | Method for the Early Detection of Renal Disease Using Proteomics |
| AU2006272913B2 (en) | 2005-07-21 | 2012-01-19 | The Johns Hopkins University | Methods of detecting and treating acute kidney injury |
| EP1757940A1 (en) | 2005-08-26 | 2007-02-28 | Cézanne S.A.S. | In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC |
| US20080133141A1 (en) | 2005-12-22 | 2008-06-05 | Frost Stephen J | Weighted Scoring Methods and Use Thereof in Screening |
| WO2007124331A2 (en) | 2006-04-19 | 2007-11-01 | Virginia Commonwealth University | Cardioprotective and other uses of mammalian target of rapamycin (m-tor) inhibitors |
| US7662578B2 (en) | 2006-04-21 | 2010-02-16 | Children's Hospital Medical Center | Method and kit for the early detection of impaired renal status |
| US20080090765A1 (en) * | 2006-05-25 | 2008-04-17 | The Trustees Of Columbia University In The City Of New York | Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage |
| GB0617429D0 (en) | 2006-09-05 | 2006-10-18 | Electrophoretics Ltd | Markers of renal transplant rejection and renal damage |
| WO2008067065A2 (en) | 2006-10-19 | 2008-06-05 | Shiv Srivastava | Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers |
| CN106908603B (zh) | 2007-01-25 | 2019-04-02 | 霍夫曼-拉罗奇有限公司 | Igfbp-7在心力衰竭评估中的用途 |
| ES2475990T5 (es) | 2007-11-15 | 2017-07-06 | Bioporto Diagnostics A/S | Uso diagnóstico de formas moleculares individuales de un biomarcador |
| US8592925B2 (en) | 2008-01-11 | 2013-11-26 | Seiko Epson Corporation | Functional device with functional structure of a microelectromechanical system disposed in a cavity of a substrate, and manufacturing method thereof |
| NZ610356A (en) | 2008-08-28 | 2015-03-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CA2735590A1 (en) | 2008-08-29 | 2010-03-04 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US20110256560A1 (en) | 2008-10-20 | 2011-10-20 | University Health Network | Methods and compositions for the detection of ovarian cancer |
| NZ607703A (en) | 2008-10-21 | 2014-09-26 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN102264230B (zh) | 2008-11-10 | 2014-12-10 | 阿斯图特医药公司 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
| MX2011008323A (es) * | 2009-02-06 | 2011-09-21 | Astute Medical Inc | Metodos y composiciones para diagnosis y prognosis de lesion renal y falla renal. |
| US9229010B2 (en) | 2009-02-06 | 2016-01-05 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US8313949B2 (en) | 2009-04-16 | 2012-11-20 | Nextcea Inc. | Detecting phospholipidosis and diagnosing lysosomal storage disorders |
| US8974491B2 (en) | 2009-06-23 | 2015-03-10 | Infarct Reduction Technologies Inc. | Methods for adaptive limb occlusion |
| CA2770382A1 (en) | 2009-08-07 | 2011-02-10 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| NZ598712A (en) | 2009-08-28 | 2014-05-30 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| NZ630277A (en) | 2009-09-21 | 2015-02-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| JP5763098B2 (ja) | 2009-12-20 | 2015-08-12 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| US20120156701A1 (en) * | 2009-12-20 | 2012-06-21 | Joseph Anderberg | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| PT2666872T (pt) | 2010-02-05 | 2016-07-08 | Astute Medical Inc | Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal |
| EP3070474A3 (en) | 2010-02-26 | 2016-12-07 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US20130210043A1 (en) | 2010-06-23 | 2013-08-15 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| NZ605698A (en) | 2010-06-23 | 2015-03-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN103874923B (zh) | 2011-08-26 | 2016-09-14 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断及预后的方法和组合物 |
| ES2734494T3 (es) | 2011-12-08 | 2019-12-10 | Astute Medical Inc | Métodos y usos para el diagnóstico de una lesión renal y de una insuficiencia renal |
| EP2923204A1 (en) | 2012-10-31 | 2015-09-30 | Astute Medical, Inc. | Quantitative lateral flow assay |
| TR201807542T4 (tr) | 2013-01-17 | 2018-06-21 | Astute Medical Inc | Böbrek hasarı ve böbrek yetmezliği teşhisi ve prognozuna yönelik metotlar ve bileşimler. |
| TWI558403B (zh) | 2013-06-04 | 2016-11-21 | 中央研究院 | 富含半乳糖脂之植物萃取物及其用途 |
| CN105556305A (zh) | 2013-06-05 | 2016-05-04 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断及预后的方法和组合物 |
| EP3617234A1 (en) | 2013-08-07 | 2020-03-04 | Astute Medical, Inc. | Assays for timp2 having improved performance in biological samples |
| US9822172B2 (en) | 2013-11-06 | 2017-11-21 | Astute Medical, Inc. | Assays for IGFBP7 having improved performance in biological samples |
| US10300108B2 (en) | 2013-12-03 | 2019-05-28 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US11243202B2 (en) | 2015-04-09 | 2022-02-08 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| JP6859334B2 (ja) | 2015-10-08 | 2021-04-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 手術前に測定した際にａｋｉのリスクを予測するためのｉｇｆｂｐ７ |
| EP3465201A4 (en) | 2016-06-06 | 2020-08-26 | Astute Medical, Inc. | MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR |
| CN110352073A (zh) | 2016-10-28 | 2019-10-18 | 机敏医药股份有限公司 | 针对timp-2的抗体用于改善肾功能的用途 |
| US11346846B2 (en) | 2017-02-06 | 2022-05-31 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US11718682B2 (en) | 2017-04-05 | 2023-08-08 | Astute Medical, Inc. | Assays for TIMP2 having improved performance in biological samples |
| WO2018208684A1 (en) | 2017-05-07 | 2018-11-15 | Astute Medical, Inc. | Use of insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2 in the management of renal replacement therapy |
-
2014
- 2014-12-03 US US15/101,118 patent/US10300108B2/en active Active
- 2014-12-03 JP JP2016535047A patent/JP2016540759A/ja active Pending
- 2014-12-03 EP EP14868424.4A patent/EP3077819A4/en active Pending
- 2014-12-03 CN CN201480073639.0A patent/CN105917229B/zh active Active
- 2014-12-03 CN CN201910275935.3A patent/CN110007084B/zh active Active
- 2014-12-03 WO PCT/US2014/068337 patent/WO2015084939A1/en not_active Ceased
-
2019
- 2019-05-24 US US16/422,520 patent/US11229676B2/en active Active
- 2019-11-07 JP JP2019202233A patent/JP7068256B2/ja active Active
-
2022
- 2022-01-24 US US17/582,999 patent/US20220143133A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016540759A5 (https=) | ||
| Deng et al. | STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib | |
| Diwan et al. | Adenine-induced chronic kidney and cardiovascular damage in rats | |
| WO2020093006A8 (en) | Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| Yao et al. | Effect of chronic intermittent hypoxia on triglyceride uptake in different tissues | |
| Kim et al. | Emphasis on repair, not just avoidance of injury, facilitates prudent stereotactic ablative radiotherapy | |
| JP2019502689A5 (https=) | ||
| Laragione et al. | The cation channel Trpv2 is a new suppressor of arthritis severity, joint damage, and synovial fibroblast invasion | |
| Wang et al. | Blocking Notch in endothelial cells prevents arteriovenous fistula failure despite CKD | |
| JP2017524704A5 (https=) | ||
| Zhang et al. | Triptolide protects rat heart against pressure overload-induced cardiac fibrosis | |
| JP2014532726A5 (https=) | ||
| Takakuta et al. | Renoprotective properties of pirfenidone in subtotally nephrectomized rats | |
| EA201990664A1 (ru) | Производные 5-[2-(пиридин-2-иламино)-1,3-тиазол-5-ил]-2,3-дигидро-1h-изоиндол-1-она и их применение в качестве двойных ингибиторов фосфатидилинозитол-3-киназ дельта и гамма | |
| EA025948B1 (ru) | КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR | |
| Ochodnicky et al. | Pioglitazone, a PPARγ agonist, provides comparable protection to angiotensin converting enzyme inhibitor ramipril against adriamycin nephropathy in rat | |
| WO2020207165A1 (zh) | 治疗脉管畸形的化合物 | |
| Monk et al. | Incidence and management of edema associated with trebananib (AMG 386) | |
| Tian et al. | Tibial transverse transport induces mobilization of endothelial progenitor cells to accelerate angiogenesis and ulcer wound healing through the VEGFA/CXCL12 pathway | |
| Zou et al. | The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo | |
| Chan et al. | Cardiorenal syndrome: the clinical cardiologists’ perspective | |
| Miyata et al. | Renoprotective effects of direct renin inhibition in glomerulonephritis | |
| Yang et al. | Expression of profibrotic genes in a murine remnant kidney model | |
| Lee et al. | Comparative portal hypotensive effects as propranolol of vitamin D 3 treatment by decreasing intrahepatic resistance in cirrhotic rats | |
| Amato et al. | Molecular-targeted therapy for renal cell carcinoma |